OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

Core Insights - OrthoPediatrics Corp. achieved record full year 2024 revenue of $205 million, reflecting a 38$15 million to $17 million [3][4] 2024 Business and Financial Highlights - The preliminary unaudited full year 2024 net revenue is$204.7 million, up from $148.7 million in 2023, marking a 38$161.1 million, representing a 45% annual growth, while international net revenue is projected at $43.6 million, a 16$52.7 million, a 40% increase from $37.6 million in Q4 2023 [6] - Domestic Q4 net revenue is expected to be$42.9 million, reflecting a 52% growth year-over-year, while international net revenue is projected at $9.8 million, a 5$235 million and $242 million, indicating a growth of 15$15 million [3] Strategic Initiatives and Market Position - The company continues to grow its market share in pediatric orthopedics, with strong performance in its Trauma and Deformity and Scoliosis businesses [4] - The specialty bracing business has been identified as a significant market opportunity, with plans for expansion and scaling in the coming years [4] Company Overview - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 70 products across trauma and deformity, scoliosis, and sports medicine categories [10] - The company distributes its products in the U.S. and over 70 countries globally [10]